| Autor: |
Charles D. Kato, Dorothy Twesigye, Vincent P. Alibu, Ann Nanteza, Julius Nsubuga, Claire M. Mugasa, Enock Matovu |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
BMC research notes. 15(1) |
| ISSN: |
1756-0500 |
| Popis: |
Objective Currently, the only available staging criterion for T. b. rhodesiense requires a lumber puncture to collect and later examine cerebrospinal fluid (CSF). This study examined the potential of plasma Neuron-Specific Enolase (NSE) in discriminating between early and late-stage patients. Results When median NSE levels were compared between early and late-stage patients, results showed a significant (P 0.9) in NSE levels were observed between early-stage patients (300 ng/mL) and controls (454 ng/mL). We used Receiver Operator Characteristic (ROC) curves to explore the likelihood of using plasma NSE as a potential stage biomarker in discriminating between early and late-stage HAT patients. Our results showed that NSE demonstrated an area under the curve (AUC) of 0.702 (95% CI 0.583–0.830). A high staging accuracy for NSE was obtained by using a cutoff of > 346.5 ng/mL with a sensitivity of 68.6% (95% CI 55–79.7%) and a specificity of 93.3% (95% CI 70.2–99.7%). Although our results demonstrate that plasma NSE is upregulated in T. b. rhodesiense sleeping sickness patients, its value in discriminating between late and early-stage patients is limited. However, future studies could consider improving its specificity by combining it with other identified plasma biomarkers. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink